1862
G. Guanti et al. / Tetrahedron: Asymmetry 9 (1998) 1859–1862
Scheme 2.
monoester 2a. The chemical correlation between monoester 2a and monoacetate 4a (from S-PPL
catalysed monoacetylation of diol 3a), through monoprotected diol 5a (R=TBDMS), allowed the (S)
configuration for monoacetate 4a to be established. This means that, in our case, the model previously
proposed by us for the acetylation/deacetylation reaction catalysed by PPL3 is still followed when
fluorine replaces hydrogen.
Further manipulations of chiral monoesters 2 and monoacetates 4, as well as full experimental details
on their achievement15 will be reported in due course.
Acknowledgements
We thank MURST and C.N.R. (Progetto Strategico) for financial support.
References
1. Banfi, L.; Guanti, G. Synthesis 1993, 1029–1056.
2. Schoffers, E.; Golebiowski, A.; Johnson, C. R. Tetrahedron 1996, 52, 3769–3826 and references therein.
3. Guanti, G.; Banfi, L.; Narisano, E. J. Org. Chem. 1992, 57, 1540–1554.
4. (a) Guanti, G.; Narisano, E.; Podgorski, T.; Thea, S.; Williams, A. Tetrahedron 1990, 46, 7081–7092. (b) Guanti, G.;
Brusco, S.; Narisano, E. Tetrahedron: Asymmetry 1994, 5, 537–540. (c) Guanti, G.; Narisano, E.; Riva, R. Tetrahedron:
Asymmetry 1997, 8, 2175–2187.
5. (a) Hudlicky, M. Chemistry of Organic Fluorine Compounds, Ellis Horwood Limited, Chichester, 1992. (b) Resnati, G.
Tetrahedron 1993, 49, 9385–9445 and references therein. (c) Ojima, I.; McCarthy, J. R.; Welch, J. T. Biomedical Frontiers
of Fluorine Chemistry, ACS, 1996.
6. Hillver, S. E.; Bjork, I.; Li, Y. L.; Svensson, B.; Ross, S.; Anden, N. E.; Hacksell, U. J. Med. Chem. 1990, 33, 1541–1544.
7. Yamazaki, T.; Yamamoto, T.; Kitazume, T. J. Org. Chem. 1989, 54, 83–91 and references therein.
8. Only 1a was a known compound (Banks, R. E.; Besheesh, M. K.; Tsiliopoulos, E. J. Fluorine Chem. 1996, 78, 39–42). 1H
NMR11: 1.32 (t, J 7.1, 6H, 2×CH3), 4.35 (q, J 7.1, 4H, 2×CH2), 7.48–7.57 (m, 2H) and 7.68 (app dd, J 1.8 and 8.8, 1H)
and 7.83–7.91 (m, 3H) and 8.08 (app d, J 1.8, 1H) (ArH) for 1b; 1.32 (t, J 7.1, 6H, 2×CH3), 4.34 (q, J 7.1, 4H, 2×CH2),
7.25–7.38 (m, 2H) and 7.58–7.60 (m, 1H) (ArH) for 1c. 19F NMR11 (CDCl3, CF3CO2H): 84.40 (s) for 1b, 78.53 (s) for
1c.
9. (a) Lal, G. S. J. Org. Chem. 1993, 58, 2791–2796. (b) Banks, R. E.; Lawrence, N. J.; Popplewell, A. L. J. Chem. Soc.,
Chem. Commun. 1994, 343–344.
10. Guanti, G.; Banfi, L.; Riva, R. Tetrahedron: Asymmetry 1995, 6, 1345–1356.
11. Spectra were recorded in CDCl3, using TMS (for 1H) or CF3COOH (for 19F) as the internal standard.
1
12. H NMR (CDCl3, TMS, after exchanging with D2O) for 3a: 3.96 and 4.04 (AB part of an ABX system, J 12.8 and 17.8
and 22.5, 4H, 2×CH2OH), 7.35–7.41 (m, 5H, Ph). 19F NMR:11 93.66–94.76 (m) for 3a, 96.70–97.76 (m) for 3b.
13. 19F NMR:11 84.09 (s) for 2a, 84.21 (s) for 2b, 78.31 (s) for 2c, 94.57–95.64 (m) for 4a, 93.80–94.94 (m) for 4b.
14. Goj, O.; Burchardt, A.; Haufe, G. Tetrahedron: Asymmetry 1997, 8, 399–408.
15. Every new compound was fully characterised and gave satisfactory analytical data.